FY2030 Earnings Forecast for Myomo Issued By HC Wainwright

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for shares of Myomo in a research report issued on Tuesday, March 10th. HC Wainwright analyst S. Lee forecasts that the company will earn $0.35 per share for the year. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share.

A number of other equities analysts have also recently weighed in on the stock. Ascendiant Capital Markets lowered their price objective on shares of Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Craig Hallum restated a “buy” rating on shares of Myomo in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $7.67.

Myomo Price Performance

Shares of MYO opened at $0.71 on Wednesday. The firm has a 50-day simple moving average of $0.86 and a two-hundred day simple moving average of $0.92. The stock has a market cap of $27.48 million, a PE ratio of -1.93 and a beta of 1.17. Myomo has a 1-year low of $0.64 and a 1-year high of $6.05. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.30 and a quick ratio of 2.10.

Institutional Trading of Myomo

A number of large investors have recently made changes to their positions in MYO. Engineers Gate Manager LP lifted its stake in Myomo by 62.8% in the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Myomo by 93.6% in the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after purchasing an additional 14,705 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Myomo in the 1st quarter valued at $75,000. Invesco Ltd. purchased a new stake in shares of Myomo during the 2nd quarter worth $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Myomo during the second quarter worth $38,000. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.